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Abstract
 
Most lymphoid malignancies are initiated by specific chromosomal translocations between
immunoglobulin (Ig)/T cell receptor (TCR) gene segments and cellular proto-oncogenes. In
many cases, illegitimate V(D)J recombination has been proposed to be involved in the translo-
cation process, but this has never been functionally established. Using extra-chromosomal re-
combination assays, we determined the ability of several proto-oncogenes to target V(D)J re-
combination, and assessed the impact of their recombinogenic potential on translocation rates
in vivo. Our data support the involvement of 2 distinct mechanisms: translocations involving
LMO2, TAL2, and TAL1 in T cell acute lymphoblastic leukemia (T-ALL), are compatible
with illegitimate V(D)J recombination between a TCR locus and a proto-oncogene locus
bearing a fortuitous but functional recombination site (type 1); in contrast, translocations in-
volving BCL1 and BCL2 in B cell non-Hodgkin’s lymphomas (B-NHL), are compatible with
a process in which only the IgH locus breaks are mediated by V(D)J recombination (type 2).
Most importantly, we show that the t(11;14)(p13;q32) translocation involving LMO2 is
present at strikingly high frequency in normal human thymus, and that the recombinogenic
potential conferred by the LMO2 cryptic site is directly predictive of the in vivo level of trans-
location at that locus. These findings provide new insights into the regulation forces acting
upon genomic instability in B and T cell tumorigenesis.
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Introduction
 
During B cell differentiation in the bone marrow, and T
cell differentiation in the thymus, V(D)J recombination
generates somatic assembly of the various noncontiguous
V, D, and J gene segments, to form a complete V(D)J exon
encoding the variable region of the B and T cell receptors
(1). The recombination process is directed by the recombi-
 
nation signal sequence (RSS),
 
*
 
 which flank each receptor
gene segment. The RSSs allow the recruitment, binding
and proper positioning of the recombination activating
gene (RAG)-1/2 proteins, which will perform the initial
cut at the border of the gene segment and the RSS. This
process generates two pairs of morphologically distinct in-
termediate DNA ends: two blunt RSSs or signal ends and
two covalently sealed hairpin coding ends. The two signal
ends are generally joined together without further modifi-
cation to form the signal joint (SJ). In contrast, coding end
hairpins are subsequently nicked and extensively modified
before ligation. Generation of a processed coding joint (CJ)
containing nucleotide deletion and additions, and a flush SJ
constitute the hallmark of V(D)J recombination.
Normally, joining takes place only between the V, D,
and J gene segments of the Ig or TCR loci. Nevertheless,
the fact that the RSS is the necessary and sufficient cis-ele-
ment for site-specific recognition and recombination para-
doxically presents a considerable threat to genomic stability
(2). Indeed, fortuitous DNA sequences in the genome re-
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sembling an authentic RSS can potentially be targeted by
mistake, and lead to illegitimate recombination events
such as chromosomal deletion, inversion, or translocations.
When such RSSs are located in or near cellular proto-
oncogenes, pathologic deregulation can ensue (3, 4). Spe-
cific chromosomal translocations between Ig/TCR antigen
receptor genes and cellular proto-oncogenes are a central
feature of lymphoid neoplasms, and in many cases, illegiti-
mate V(D)J recombination has been proposed to be in-
volved in the process. However, the actual mechanism by
which cells undergo illegitimate recombination, and the
role of the normal V(D)J recombination in the process are
still poorly understood. This is due to the fact that to date,
knowledge of chromosomal translocation mechanisms is
mainly derived from the posttranslocation observation of
breakpoints from the derivative chromosomes. In absence
of functional systems, the main criteria which have been
traditionally used to define a V(D)J-mediated translocation
are therefore based on the similarity of the translocation
breakpoints to the products of V(D)J recombination: (a)
involvement of an Ig/TCR segment as one of the translo-
cation partners; (b) identification of a RSS-like motif near
the germline proto-oncogene sequence; (c) recurrent
breaks at the border of the RSS motifs on both immune
and nonimmune loci; (d) presence of nucleotide additions
and deletions at one of the breakpoints; (e) generation of a
SJ at the other breakpoint. However, for various reasons,
some due to limitations of study in humans, some inherent
to the mechanism of the translocation, fulfillment of all
criteria has not always been manageable in vivo. In partic-
ular, identification of a RSS-like motif based on the pri-
mary sequence can be misleading. RSSs normally consist
of highly conserved heptamer and nonamer motifs sepa-
rated by a spacer sequence of 12 or 23 bp (Table I). Nev-
ertheless, most RSSs flanking V, D, and J segments contain
some degree of polymorphism in their sequence, and this
 
has been shown to be a major factor affecting the relative
representation of gene segments in the primary repertoire
(5). Depending on the position, alterations in the hep-
tamer, nonamer, or spacer sequences (e.g. Tables I–III)
can be extremely deleterious for recombination (6–10).
Furthermore, multiple variations from consensus can result
in synergistic effects (11), and the many combinations of
heptamer, nonamer, and spacer variants have obviously
not all been analyzed. Thus, despite abundant in vivo and
in vitro studies, apart from the mandatory presence of the
heptamer’s 5
 
 
 
CAC3
 
  
 
(2), there is to date no precise rule
allowing the prediction of the recombinogenic potential of
a RSS variant based solely on its sequence. This is espe-
cially true for fortuitous RSSs bearing poor resemblance to
consensus sequences, as often the case in proto-oncogene
loci (Table II). To assess if such RSSs are truly involved in
V(D)J recombination, they have therefore to be tested in
functional assays (12).
 
Table I.
 
Authentic RSSs Flanking V(D)J Gene Segments
 
RSS Heptamer Spacer Nonamer
 
Consensus
 
CACAGTG ACAAAAACC
 
V
 
 
 
A2b
 
CACAGAG
 
12
 
ACAGAAACC
 
V
 
 
 
A27
 
CACAGTG
 
12
 
ACAAAAACC
 
J
 
 
 
l
 
CACAGTG
 
a
 
23
 
ACAAAAACC
 
J
 
H
 
6
 
b
 
CACAATG
 
a
 
22
 
ACAAAAACC
 
J
 
 
 
2-7
 
CACGGAG
 
a
 
12
 
ATGCAAACC
 
J
 
 
 
l
 
CACAGCA
 
a
 
12
 
CCAAAAACC
 
D
 
H
 
3.10
 
CACAGTG
 
12
 
TCAAAAACC
 
D
 
 
 
2
 
CACAGTG
 
23
 
ACAAAAACT
 
D
 
 
 
1
 
CACAATG
 
23
 
ACAAAAACC
 
Mismatches from consensus are underlined.
 
a
 
Sequence shown in reverse complement orientation.
 
b
 
Indicates changes from the wt sequence in the constructs (see Materi-
als and Methods).
 
Table II.
 
Fortuitous RSSs at the Vicinity of
Proto-oncogene Breakpoints
 
Fortuitous RSS
Proto-oncogene Heptamer Spacer Nonamer
Consensus
 
CACAGTG ACAAAAACC
 
TAL2 (9q32)
 
CACTGTG
 
a
 
13
 
ATAAAAATA
 
LMO2 (11p13)
 
CACAGTA
 
a
 
12
 
GCAATAATT
 
TAL1 (1p34)
 
CACACCG
 
22
 
CGAAAAAGG
 
BCL1 mtc (11q13)
 
CACATCG
 
12
 
TTGCGTGGA
CACTGCA
 
12
 
CTGTGATTA
CACCTGG
 
12
 
CGTGAACGA
CACATCC
 
12
 
CAGGACCTG
CACGCCA
 
a
 
23
 
AGCTCTTGC
CACGAAG
 
a
 
23
 
ACGCAGATA
CACGCAG
 
a
 
23
 
TGTTTCAGA
CACTTTT
 
a
 
23
 
CGAATATGC
CACAGTC
 
a
 
23
 
TTATGCTCC
CACGCAA
 
a
 
23
 
GCAGCCTTA
CACACCG
 
a
 
23
 
AATGACCAA
 
BCL mbr (18q21)
 
CACAGAC
 
12
 
CTCCTGCCC
CACCCAG
 
12
 
CTCCTTCCG
CACCAAG
 
12
 
CTGTGGTAT
CACAGGA
 
a
 
23
 
TTGACAATG
CACTTTG
 
a
 
23
 
AATATTTTG
CACAGGT
 
a
 
23
 
AACGACCAC
CACTGCA
 
a
 
23
 
GCCATGAGA
CACGTAA
 
a
 
23 ACCATAGAT
CACCATAa 23 CCATCTGGA
Maximum matches of the nonamer are shown with an appropriate 12
or 23-RSS   1 bp.
aSequence shown in reverse complement orientation.87 Marculescu et al.
In this report, we used an extra-chromosomal V(D)J re-
combination assay to directly and functionally test which
of several proto-oncogene sequences is able to target
V(D)J recombination. The breakpoint regions and flank-
ing genomic sequences of five typical translocations pre-
sumably resulting from V(D)J recombination mis-target-
ing, were therefore assayed for recombination: BCL2/IgH
fusion in t(14;18)(q32;q21) (13–15), which is the most
frequent translocation in B cell non-Hodgkin’s lympho-
mas (NHL), and the hallmark of follicular lymphomas
(FLs); BCL1/IgH fusion in t(11;14)(q13;q32) (16), also
present in a substantial fraction of mature B-NHL;
TCR /TAL2 fusion in t(7;9)(q34;q32) (17), LMO2/
TCR  fusion in t(11;14)(p13;q11) (18–21), and TAL1/
TCR  fusion in t(1;14)(p34;q11) (22–25), all recurrently
involved in the development of pediatric T cell acute
lymphoblastic leukemia (T-ALL; reference 26). Our re-
sults clearly show that fortuitous sites in the LMO2 and
TAL2 proto-oncogenes can target V(D)J recombination at
a frequency comparable to physiological RSSs. Similarly,
the region of the TAL1 proto-oncogene involved in most
translocation breakpoints also contains a functional re-
combination site, although triggering V(D)J recombina-
tion at a much lower frequency. In contrast, fortuitous
sites present in the BCL2 major breakpoint region (mbr)
and BCL1 major translocation cluster (mtc), are not able
to initiate V(D)J recombination at relative frequencies
comparable to the ones corresponding to the breaks ob-
served in vivo. Thus, our results support the presence of at
least two distinct mechanisms by which V(D)J recombina-
tion leads to translocation in lymphoid neoplasms: in some
translocations, illegitimate V(D)J recombination would
occur between a legitimate Ig or TCR locus and an ille-
gitimate proto-oncogene locus bearing a fortuitous, but
functional RSS; in a second category, however, only the
breaks at the immune locus would be mediated by V(D)J
recombination. Breaks at the nonimmune locus bearing
the proto-oncogene, would be initiated by other (yet un-
known) mechanisms, and would subsequently invade the
V(D)J synaptic complex during the rearrangement pro-
cess. Most importantly, our precise quantification of the
recombinogenic potentials of the TAL2 and LMO2
proto-oncogene breakpoint regions show that mis-target-
ing by the V(D)J recombination can constitute a consider-
able risk of genomic instability. Indeed, we report that the
t(11;14)(p13;q11) involving D 2/LMO2 recombination
can be detected at a surprisingly high frequency in thymus
of healthy individuals, and that the recombinogenic po-
tential of LMO2 is directly predictive of the actual in vivo
rate of translocation.
Materials and Methods
Recombination Substrates. The organization of our recombina-
tion plasmids was described previously (27; Fig. 1). Briefly, the
two sequences to be tested for VDJ recombination are separated
by a termination signal (oop). The Ptac promoter will transcribe
the chloramphenicol acetyltransferase (CAT) gene when trans-
formed in E. coli only when the termination signal was previously
deleted by recombination in eukaryotic cells. All constructs used
in this study were derived from Comp21 (10). Each sequence
tested for recombination is flanked by unique restriction sites and
forms therefore a cassette which can be easily exchanged (up-
stream cassette: Mlu I/Sal I, downstream cassette: SpeI/Sac II or
Not I; Fig. 1). Cassettes were PCR-amplified from human ge-
nomic DNA (primers are listed in Table IV). Inverted cassettes
were cloned blunt except for LMO2i and D 2i (Table IV). The
JH6 heptamer was modified to a perfect consensus by PCR site-
directed mutagenesis. The 6131 cassette is a  400 bp lacZ frag-
ment amplified from the pCR2.1 vector (Invitrogen) after SacI/
NsiI deletion of the MCS, and allows white/blue screening. Cas-
settes in all constructs were confirmed by sequencing and are il-
lustrated in Fig. 2.
Transfection and Harvesting. 18.8 Abelson murine leukemia
virus transformed pre-B cells (2   107) were transiently trans-
fected with 20  g of QIAGEN-purified plasmid (QIAGEN) by
electroporation with a twin pulse (750 V/25  F, 128 V/1,500
 F) using an EasyJect device (EquiBio). After 10 min on ice the
cells were resuspended in 10 ml of RPMI 1640 supplemented
with 10% FCS, 2 mM glutamine, and 1 mM caffeine. After 48 h,
plasmids were recovered from the transfected cells by alkaline ly-
sis, and phenol/chloroform extracted. DpnI-digested plasmids
were then introduced into chemically competent TOP 10 E. coli
(Invitrogen), and plated on ampicillin (50  g/ml) and chloram-
phenicol (5  g/ml). For the lacZ-containing substrates, X-Gal
was added to the plates.
Screening of Recombinants. Clones were screened by PCR us-
ing primers located upstream and downstream of the recombina-
tion cassettes (CAACTTCTGGTCCGGTAACGTGCTG and
CGATGCCATTGGGATATATCAACGGTGG; Fig. 1), fol-
lowed by direct sequencing as described previously (28). PCR
screens were performed from the colonies by resuspending them
directly in the PCR mixture, and amplifying for 30 cycles (30 s at
94 C, 30 s at 60 C, and 1 min at 72 C). Colonies negative in the
PCR screen were miniprepped and analyzed by BamHI digest.
Only minipreps showing at least one BamHI cut were analyzed
further. The (6131-DH3i)/D 2i construct allowed a first assess-
ment of the recombination site based on blue/white screening.
This estimation was confirmed by sequencing 10 blue colonies
and all white colonies for each transfection.
DNA Samples. Thymus samples were obtained from other-
wise healthy children undergoing cardiac surgery. This study was
Table III. Fortuitous RSS in the Core Plasmid
RSS Heptamer Spacer Nonamer
Consensus CACAGTG ACAAAAACC
 150 CACATTAa 12 ATTAATTGT
 200 CACAGGA 12 GACATTGAG
 250 CACAACA 12 ATCGGCAGG
 1200 CACAGTC 12 CCTGGGTCG
 3490 CACAGCG 12 GTAAGTATC
 6131 CACAACAa 12 GCATAAAGT
Only the fortuitous RSSs which underwent recombination are
represented. 
aSequence shown in reverse complement orientation.88 Genomic Instability by Cryptic RSS
approved by the local ethics committee. In all cases informed
consent was obtained from the parents. Tissue samples were fro-
zen on dry ice within 1 h from excision. High molecular weight
DNA was prepared according to standard procedures. Quality of
the DNA preparation was controlled by PCR amplification of
the germline LMO2 breakpoint region (CCGTGCACCGA-
AATTATTGCTGGGTAA; GTACCCACTTTGCAGGGTT-
GTTGAGTGG, same conditions as calibration below) on serial
dilutions of thymus DNA (100 ng, 10 ng, 1 ng, 0.1 ng). All prep-
arations gave similar calibration curves.
Thymus PCR Assays. The “multiple tube” method has been
described previously (29). A two-step nested PCR protocol was
performed on 5  g DNA with appropriate translocus D 2/
LMO2 (primary: TCCCTGGTCCAGTCAACTTCCTG, GAG-
ATGATCAGATCCGTGCACCG, secondary: GCTGTGTT-
TGTCTCCTGAGGCATGG, CCGTGCACCGAAATTATT-
GCTGGGTAA), and D 2/J 2.7 (primary: TCCCTGGTCC-
AGTCAACTTCCTG, GGCGGGATTCAGGTGGAAGG,
secondary: GCTGTGTTTGTCTCCTGAGGCATGG, GAG-
CTCGGGGAGCCTTAGAGG) primer pairs. PCR conditions
used were as follows: 32 cycles (30 s at 94 C, 30 s at 64 C, and 1
min at 72 C). PCR products were cloned in TA (Invitrogen)
and analyzed by sequencing. PCR conditions used for the cali-
bration assay were identical except the number of cycles (20).
Serial dilutions of the calibration plasmids (100 pg, 10 pg, 1 pg,
100 fg, 10 fg, 1 fg) were performed in 1  g DNA from the hu-
man lymphoma cell line RL7.
Online Supplemental Material. Sequence libraries of the junc-
tions. Upstream and downstream sequences of the given recom-
bination are indicated. For recombinants using V(D)J recombina-
tion, numbers in parenthesis indicate the status of the coding end
processing (0   precise,  n   deletion, p   n   P nucleotide).
P nucleotides are shown in italics. N nucleotides are represented
in bold characters. Nucleotides in parenthesis could belong to ei-
ther upstream or downstream sequence or both using homology-
directed recombination. For recombinants using break/repair,
the location of the break is indicated. Numbers indicate the loca-
tion in the core plasmid. Breaks in the cassettes are designed by
the name of the cassette. If a break occurred in a cassette contain-
ing an authentic RSS (a) or a specific proto-oncogene RSS (b),
the location of the break relative to this RSS is indicated (3  or
5 ). Junctions are ordered according to break location (5  to 3 )
in the upstream sequence. The online supplemental se-
quences are available at http://www.jem.org/cgi/content/full/
195/1/85/DC1.
Results
Assessment of V(D)J Targeting of Proto-oncogene Sequences by
the Extra-chromosomal Recombination Assay. To function-
ally test several proto-oncogene sequences for their ability
to target V(D)J recombination, we adapted the extra-
chromosomal recombination assay (see general principle in
Materials and Methods). This assay typically tests V(D)J
recombination between two authentic RSSs derived from
immune gene segments, which generally recombine at
high frequency. In this case, most if not all recombination
Table IV. Primers
Cassette Site Sequence (5 -3 )
LMO2 SalI GGCCGTCGACATCCGTGCACCGAAATTATTGCTGGG
TAAGACAATACTGTG
MluI GTCCACGCGTAGGAAAGAGCTTTCCGAAGTTCCAAG
GCTATGTAACACACACAGTATTG
D 2 SpeI CCATACTAGTCACAAACCCCAAGGCAG
NotI CCTCCGCGGCCGCAAAGCAGGGAGGGAAG
D 1 MluI CTCAACGCGTCCTGAGGACAGTGCCTG
SalI TGTCGTCGACCACAGTCTTGGTCTG
TAL2 SpeI CCGGACTAGTGTTTTATTTTTATATCTCCAGTAAGT
CACAGTGTGAC
NotI GACCGCGGCCGCTTTATCGAGCAACCACAGTGCAAG
TCACACTGTGAC
TAL1 MluI AGGAACGCGTCCAAACACCTGCAG
SalI CTTCGTCGACACCGTTTCCACCG
D 2i NotI CCATAGCGGCCGCCACAAACCCCAAGGCAG
SpeI TACAACTAGTGGAAAGCAGGGAGGGAAG
BCL1 mtc MluI CTACACGCGTACTTGTGGGTTG
SalI CAGTGTCGACCAGTGCCCCAG
BCL2 mbr SpeI TGAGACTAGTTCAGTTAAAAATCCAG
NotI GCAAGCGGCCGCCATTAAAATG
JH6 SpeI TATGTCGACCACTAGTGGTCTGGCTTCTGAGGGGTC
AGG
NotI TCCTCGCGGCCGCCCAGTGCCGTCCCCTCTG
DH3.10 MluI GTGTCACGCGTGTATTACTATGGTTCGGGGAG
LMO2i SalI CCATGTCGACTGGCGTTGGGAGGGCAG
MluI GGCCACGCGTATCCGTGCACCGAAATTATTGCTGGG
TAATACAATACTGTG
SalI GTCCGTCGACAGGAAAGAGCTTTCCTAAGTTCCAAT
GCTATGTAACACACACAGTATTG
6131 SalI CGACTGGTCGACGGGCAGTGAGCG
XhoI GATCCTCGAGCCCGCCGCGCTTAATG
BCL2 mbrf MluI TTTTACGCGTCAGGTGTGGAATATGGGGGTTATCTG
SalI TTTTGTCGACGTACAGTTCTGGGGCCAAGAGG
3 BCL2 SpeI TTTTACTAGTGACCGTCATACATGGG
SacII AAATCCGCGGTTCTTAGTATGAGGTTG
J 2.7 NotI TTTCGCGGCCGCCAGCAGGCTGACCGTGCTGG
SacII CTGACCGCGGACACCCAGCTCCTCCAG
J 1 XhoI GGTCCTCGAGACTCCTCAGACAACAG
SalI TTATGTCGACCTCCTTAGATGGGAGGATG
Figure 1. Recombination substrate (not to scale). The upstream cas-
sette is comprised between M (Mlu1) and S (Sal1). The downstream cas-
sette is comprised between Sp (Spe1) and Sc (Sac2) or N (Not1). The au-
thentic RSS is shown as a triangle (a). Fortuitous RSSs are represented as
incomplete triangles: b, fortuitous RSS observed in proto-oncogene
translocation breakpoints, c, other potential fortuitous RSS in proto-
oncogene flanking sequence, d, other fortuitous RSS in core plasmid se-
quence. Pathways 1–3: V(D)J recombination; Pathway 4: BR. Horizontal
arrows indicate the location of the PCR screen primers.89 Marculescu et al.
events obtained correspond to V(D)J recombination be-
tween these two sites. The substitution of one of the two
authentic RSSs by a “fortuitous” site containing numerous
mismatches from consensus (also called “cryptic” site), re-
sults in a decrease in the overall recombination frequency,
and in the apparition of other low level recombination
events (2). In our assay, we distinguish three distinct re-
combination events: (a) V(D)J recombination at the “spe-
cific” sites, i.e., between the authentic RSS and the fortu-
itous RSS we wish to assay (illustrated by pathway 1 in
Fig. 1); (b) V(D)J recombination at “nonspecific” sites,
i.e., between the authentic RSS and other fortuitous
RSSs. Such fortuitous RSSs can be located either in the
genomic sequence flanking the “specific” RSS (pathway 2
in Fig. 1), or in the plasmid core sequence (pathway 3 in
Fig. 1); (c) Unspecific break/repair (BR) recombination
events, which are defined here as not mediated by V(D)J
recombination, and which constitute the background of
the assay (e.g. pathway 4 in Fig. 1, no RSS involved). The
potential for V(D)J targeting of the specific RSS tested is
therefore assessed relatively to the other 2 “competing”
recombination events. Fairly good RSSs (recombining in
the range of authentic RSSs) are expected to constitute
the vast majority of the readout. In contrast, increasingly
poor RSSs should appear at decreasing relative rates in the
total readout.
Five representative proto-oncogene breakpoint regions
which have been proposed to target V(D)J recombination
through fortuitous RSSs were assayed: TAL2, LMO2,
TAL1, BCL1 mtc, and BCL2 mbr. For TAL2, LMO2, and
TAL1, one particular fortuitous RSS has been observed in
vivo in most of the breakpoints characterized so far and
proposed to be responsible for V(D)J recombination target-
ing (Table II). The genomic regions containing the RSSs
were therefore PCR-amplified and cloned in recombina-
tion substrates (Fig. 2, lines 1–3); at the BCL1 mtc and the
BCL2 mbr, however, most breaks observed in vivo cluster
in a region of  400 bp (14, 30) containing several potential
cryptic RSSs (Table II; references 31 and 32). In this case,
the whole  400 bp mbr and mtc regions were PCR-
amplified and cloned in the recombination substrates (Fig.
2, lines 4 and 5). In the corresponding translocations ob-
served in vivo, the proto-oncogene sequences are all fused
to authentic Ig or TCR coding sequences. Furthermore,
they preferentially use a specific recombination partner.
Such “natural” RSS partners were therefore used as the
Figure 2. Schematic representation of the recombi-
nation cassettes (to scale). Upstream and downstream
cassettes are represented with their authentic and fortu-
itous RSSs (see legend to Fig. 1). RSSs with 12 bp
spacers are white, those with 23 bp spacers are black.
For clarity, fortuitous RSSs in cassettes containing au-
thentic RSSs, or fortuitous RSSs without an authentic
RSS matching partner are not represented. Cassettes
are delimited by lozenges.90 Genomic Instability by Cryptic RSS
matching recombination partners in the recombination
substrates. Thus, five basic constructs were at first generated
and assayed: D 1/TAL2, LMO2/D 2, TAL1/D 2i, BCL1
mtc/JH6, and BCL2 mbr/JH6. As reference, two constructs
containing consensus or near-consensus RSSs derived from
immune gene segments were also assayed (V A2.27/J 1,
and DH3–10/JH6; Fig. 2, lines 6 and 7).
Fortuitous RSSs in TAL2, LMO2, and TAL1 Proto-onco-
gene Breakpoint Regions Are Able to Target V(D)J Recombina-
tion. Results in Table V show that the control plasmids
(V A2.27/J 1, and DH3–10/JH6) gave rise to a high fre-
quency of recombination in our assay (average 250 to
3,700 clones per transfection). As expected with authentic
RSSs, most recombination events from these two con-
structs displayed V(D)J recombination at the specific RSSs
( 98–100%). However, and as previously described, large
differences in the recombination frequency were found
between the two constructs, as the result of variations in
the RSSs involved. Similar results were obtained for the
D 1/TAL2 and LMO2/D 2 constructs: a vast majority of
the recombination occurred between the specific RSSs as-
sayed, i.e., the authentic immune RSS (D 1 or D 2) and
the TAL2 or LMO2 fortuitous RSS ( 96%). Neverthe-
less, a low level of recombination also occurred between
the D 1 or D 2 RSSs and other fortuitous sites located in
the core plasmid, competing therefore with TAL2
( 1200, 2%) and LMO2 ( 200, 2%;  250, 2%) (see Ta-
ble III for sequences of cryptic RSSs). Altogether, these
results suggest that both TAL2 and LMO2 sequences con-
tain functional RSSs (see competition substrates analysis
below). This is in agreement with recent data from Ragha-
van et al. (12), who also studied the LMO2 RSS in a simi-
lar recombination assay. Sequence analysis of the D 1/
TAL2 (n   38) and LMO2/D 2 (n   26) coding joints
confirmed normal features of V(D)J recombination, in-
cluding break at the coding segment/RSS border, P and N
nucleotide additions and deletions (summarized in Fig. 3,
A 1, for LMO2/D 2; full sequence libraries are shown in
the online supplemental sequences). Importantly, these
features are also similar to the ones observed in vivo at
most derivative chromosome 7 and 14 breakpoints in t(7;9)
D 1/TAL2 (17) and t(11;14) LMO2/D 2 fusion (19)
(21), respectively.
For the TAL1/D 2i construct, recombination rates are
much lower than consensus RSSs (Table V). The major-
ity of these events correspond to V(D)J recombination of
the D 2 3 RSS with cryptic RSSs other than TAL1
(69%). Three different cryptic RSS located in the core
plasmid were found recombined:  150, 29%;  6131,
34%;  3490, 5%. Nevertheless, two clones (5%) showed
recombination at the specific TAL1 RSS, and sequence
analysis of the two coding joints confirmed normal fea-
tures of V(D)J recombination, including presence of a P
nucleotide (see online supplemental sequences). Addi-
tionally, cleavages occurred at the immediate border of
both the TAL1 RSS (in one case at the exact border, in
the other case with 1 nucleotide deletion) and the D 2
RSS (in one case with a P nucleotide, in the other case 2
nucleotides deletion). That the two breaks would have
occurred by chance at both RSS borders in two indepen-
dent clones by non-V(D)J–mediated mechanisms is very
unlikely. This suggests that TAL1 fortuitous RSS can
mediate V(D)J recombination, although at very low lev-
els. Importantly, none of the competitor cryptic sites
present within the genomic TAL1  400 bp flanking re-
gion (Fig. 2, line 3, “c” RSSs) underwent recombina-
tion. This observation is in agreement with the identifi-
cation of this cryptic site as the only RSS mediating the
TAL1/TCR  translocation in this 400 bp region in vivo
(22, 23).
Table V. Recombination Substrates
V(D)J recombination
Vector No. Ta No. clonesb No. Ac Specific RSSd Other RSSe BRf
V A2.27/J 18  30,000 ( 3,700) 50 50 (100%) 0 (0%) 0 (0%)
DH3.10/JH63  750 ( 250) 47 46 (98%) 0 (0%) 1 (2%)
D 1/TAL2 10  570 ( 57) 110 106 (96%) 2 (2%) 2 (2%)
LMO2/D 26  200 ( 34) 51 49 (96%) 2 (4%) 0 (0%)
TAL1/D 2i 6  110 ( 18) 38 2 (5%) 26 (69%) 10 (26%)
BCL1 mtc/JH6 5 42 ( 8) 37 0 (0%) 0 (0%) 37 (100%)
BCL2 mbr/JH6 4 44  ( 11) 37 0 (0%) 0 (0%) 37 (100%)
aTotal number of independent transfections.
bTotal number of clones obtained (average number of colonies per transfection).
cTotal number of clones analyzed (PCR screen and/or sequencing).
dV(D)J-mediated recombination between two authentic RSSs (V A2.27/J 1, DH3.10/JH6) or between one authentic RSS and the fortuitous RSS
identified at the proto-oncogene breakpoints in vivo.
eV(D)J-mediated at other fortuitous sites (within the flanking proto-oncogene sequence or in the core plasmid).
fBR-mediated recombination (defined as not mediated by V(D)J).91 Marculescu et al.
In conclusion, these results functionally demonstrate that
the fortuitous RSSs of TAL2, LMO2, and TAL1 are able
to undergo V(D)J recombination. The data strongly sup-
port the view that t(7;9)(q34;q32), t(11;14)(p13;q11), and
t(1;14)(p34;q11) translocations can result from bona fide
V(D)J recombination between a legitimate TCR locus and
an illegitimate proto-oncogene locus bearing a fortuitous
but functional RSS. We will refer further to this category
of translocations as “type 1.” Our results also suggest that a
cryptic site with very low recombinogenic potential such as
TAL1 can be involved in such type 1 translocation in vivo.
Fortuitous RSS in BCL2 or BCL1 Breakpoint Regions Are
Not Able to Target V(D)J Recombination in Extra-chromosomal
Substrates. At the lower end of the recombination spec-
trum in Table V, the BCL2 mbr/JH6 and BCL1 mtc/JH6
constructs showed sublevels of recombination events, with
an average of  10 clones per transfection. Sequence analy-
sis of these clones revealed that none of the junctions com-
plies with the criteria of V(D)J recombination (see online
supplemental sequences). In particular, breaks are not local-
ized at the immediate border of any of the potential cryptic
RSSs in the BCL2 mbr and in the BCL1 mtc, or at the
border of the authentic JH6 RSS (summarized in Fig. 3, A
2), in sharp contrast to the other constructs (e.g. LMO2/
D 2, Fig. 3, A 1). This is in agreement with the finding of
similar break distribution in experiments performed in cells
devoid of RAG activity (CHO, not shown). However,
junctions generated by BR do not necessarily indicate the
precise site of cleavage. To confirm our general interpreta-
tion of the breaks, and to exclude the possibility that some
of the BCL2 mbr/JH6 and BCL1 mtc/JH6 breaks would
occur at unidentified cryptic RSSs, we also tested the for-
mation of signal joints. The presence of the signal joint in
addition to the coding joint allows to diagnose unambigu-
ously the use of the V(D)J mechanism in the recombina-
tion process. To do so, each of the two cassettes of the
BCL2 mbr/JH6 plasmid were inverted so that the retained
product would correspond to a SJ instead of a CJ (Fig. 2,
line 8, BCL2 mbri/JH6i). As a control, we also inverted the
two cassettes of the LMO2/D 2 construct (Fig. 2, line 9,
LMO2i/D 2i). As shown in Fig. 3 B, 100% of the LMO2i/
D 2i clones (10/10) corresponded to the specific SJ, while
none of the BCL2 mbri/JH6i clones (0/10) showed SJ for-
mation. These results confirm our previous break diagnos-
tic based on the CJ, and indicate that the recombined
clones obtained for the BCL2 mbr/JH6 and BCL1 mtc/JH6
pairs are indeed not derived from V(D)J recombination,
but from unspecific BR. Thus, none of the fortuitous 12-
RSSs in the  400 bp BCL2 mbr and BCL1 mtc were able
to target V(D)J recombination with the JH6 RSS as the
“natural” recombination partner.
In the BCL2 mbr/JH6 and BCL1 mtc/JH6 substrates,
however, the complete absence of recombination of the
JH6 RSS with other fortuitous cryptic sites in the plasmid
core sequence contrasts with the situation in other con-
structs (Table V, other RSS: 0%). This might be due to
Figure 3. Schematic representation of the break-
points distribution (to scale). See also legend to Fig. 1.
Black cones indicate the location and frequency of the
breaks. Breaks located outside the drawing in BCL2
mbri /JH6i are indicated by dashed arrows.92 Genomic Instability by Cryptic RSS
the low recombination frequency of the JH6 RSS due to
the presence of a 22-bp spacer. Although high enough to
target recombination with another authentic RSS such as
DH3.10, this frequency might be too low to generate de-
tectable levels of recombination to cryptic sites in the core
plasmid or within the BCL2 mbr and BCL1 mtc segments.
To test this possibility, a new BCL1 mtc construct was de-
signed in which the JH6 segment was substituted by the
D 2 segment, in signal joint configuration (Fig. 2, line 10,
(BCL1 mtci-6131)/D 2i). As an internal control for V(D)J
recombination, a known cryptic site was also cloned in the
plasmid. We used the “6131” cryptic site described by
Lewis and colleagues, which was estimated to recombine
at  1% of the activity of a consensus RSS (2). As a refer-
ence, we constructed a similar plasmid, containing the
DH3 segment instead of BCL1 mtc (Fig. 2, line 11, (6131-
DH3i)/D 2i). As shown in Table VI, the substitution of
JH6 by D 2 as a recombination partner in the (BCL1 mtci-
6131)/D 2i construct still did not result in targeting V(D)J
recombination at the BCL1 mtc fortuitous RSSs (0%).
However, in presence of D 2, the vast majority of recom-
bination events (98%) consisted of V(D)J recombination
between D 2 and other fortuitous sites (including 6131,
 79%), leaving only 2% of BR events. The relative re-
combination rate between 6131 and DH3 in the 6131-
DH3i/D 2i construct confirmed that 6131 recombines in
our hands at  1–2% of the activity of an authentic RSS.
Thus, it can be estimated that the recombinogenic poten-
tial of all BCL1 mtc fortuitous sites together is  1% the
rate of cryptic sites such as 6131, or  0.01% the rate of a
consensus RSS.
Importantly, in the BCL2 mbr/JH6 and BCL1 mtc/JH6
constructs, only the appropriately oriented fortuitous 12-
RSSs (5 CAC3 ) were tested (Fig. 2, lines 4 and 5, white
RSSs in BCL2 mbr and BCL1 mtc cassettes). However, in
vivo, numerous fortuitous 23-RSS in opposite orientation
(3 GTG5 ) could target recombination by recombining
with the authentic 12-RSSs of the DH segments, and these
potential cryptic sites also had to be tested in our assay. In
the (BCL1 mtci-6131)/D 2i construct, the D 2 contains
two RSSs (Fig. 2, line 10): one 23-RSS in SJ configuration
(black RSS) and one 12-RSS in CJ configuration (white
RSS). In this construct, both potential 12- and 23- fortu-
itous RSSs of the BCL1 mtc in the proper orientation rela-
tive to the translocation breakpoints observed in vivo
(white and black RSSs, respectively, in the BCL1 mtc cas-
sette), were therefore assayed at once. The inability of the
BCL1 mtc to target V(D)J recombination at the sensitivity
estimated above takes therefore into account all potential
12- and 23 cryptic sites in the BCL1 mtc. To test in a sim-
ilar way both the 12- and 23 fortuitous RSSs of the BCL2
mbr, this region (here flanked by an additional  800 bp of
surrounding genomic DNA) was also cloned with the D 2
partner (Fig. 2, line 12, BCL2 mbrf/D 2). Similar results
were found for this construct (Table VI). No recombina-
tion of the BCL2 mbr cryptic RSSs occurred (0%), while
V(D)J recombination of D 2 to other fortuitous sites
( 250, 94%;  150, 6%) took place in 70% of the cases. As
expected, the absence of the  6131 RSS resulted in a
lower V(D)J recombination versus BR ratio than for the
(BCL1 mtci-6131)/D 2i construct. Thus, as the recombi-
nation rates of the cryptic sites above are lower than that of
6131, a recombinogenic potential of  0.01% the rate of a
consensus RSS can also be estimated for the 12- and 23
fortuitous RSSs in the BCL2 mbr.
Altogether, these results show that fortuitous RSSs in
BCL2 or BCL1 breakpoint regions are not able to target
V(D)J recombination in the limit of detection of our extra-
chromosomal assay (estimated as at least 1:10,000 the rate
of a consensus RSS).
Fortuitous RSSs in the BCL2 mbr Cannot Account for the
Relative Rate of the t(14;18)(q32;q21) In Vivo. What is the
significance of the absence of V(D)J recombination at cryp-
tic sites in our ex vivo assay? TAL1/D 2i data shows that
the frequency of V(D)J recombination can be lower than
the frequency of BR (Table V). Nevertheless, this low
V(D)J recombination event recapitulates qualitatively the
involvement of the V(D)J recombination in the TAL1/
TCR  translocation process as observed in vivo. Thus, al-
though indicative of the likelihood of usage of the V(D)J
recombination, the relative frequency of BR versus V(D)J
recombination events does not represent a physiological
limit to the potential involvement of V(D)J recombination
in the translocation processes. In other words, BCL1 mtc
and BCL2 mbr breaks in vivo could still be the result of ex-
tremely low levels of V(D)J recombination, but with a fre-
quency under the sensitivity of our ex vivo assay. To set
Table VI. Recombination Substrates. Competition with Cryptic 
Site 6131
V(D)J recombination
Vector
(external-internal)
No.
T
No.
A
Specific
RSS
Other
RSSa BR
(BCL1 mtci-6131)/D 2i 6 82 0 (0%) 80 (98%) 2 (2%)
(6131-DH3i)/D 2i 2 293 283 (97%) 7 (2%) 3 (1%)
BCL2 mbrf/D 2 7 23 0 (0%) 16 (70%) 7 (30%)
aIncluding 6131.
Table VII. Relative Rates of V(D)J Recombination at BCL2 mbr 
and 3 BCL2 Loci
V(D)J recombination
Vector
(internal-external)
No.
T
No.
clones
No.
A3  BCL2 : BCL2 mbr
In vivoa NA NA 40 2 (5%) : 38 (95%)
(3 CBL20BCL2 mbrf)/D 2 3 105 41 29 (100%)b : 0 (0%)
aReference 33.
bThe 12 remaining clones consist of BR located outside BCL2 mbrf.93 Marculescu et al.
the sensitivity of our assay in perspective of the in vivo pro-
cess, we sought therefore to compare relative frequencies
of V(D)J-mediated breaks occurring at the BCL2 locus in
vivo and ex vivo. In rare cases of FL, breaks have been re-
cently proposed to occur through V(D)J recombination at
two fortuitous RSSs located outside the BCL2 break clus-
ters (5  of BCL2 and 3  of mbr; reference 33). Although
not leading to t(14;18) translocation per se, these cases re-
sulted in the transposition of the BCL2 gene into the IgH
locus, and in the overexpression of BCL2 in a manner sim-
ilar to the t(14;18). It was estimated that this transposition
event occurs in  5% of FL cases (2/40). Thus, if one as-
sumes that both the transposition breaks and the BCL2 mbr
breaks result from a V(D)J-mediated process at fortuitous
RSSs, the relative in vivo rate of V(D)J recombination at
the transposition loci and at the BCL2 mbr should be
 5:95% (Table VII). To estimate the sensitivity of our ex
vivo assay compared with the in vivo situation, we con-
structed and assayed a competition substrate containing both
the 3 BCL2 region containing the fortuitous RSS involved
in the transposition and the large BCL2 mbrf segment, (Fig.
2, line 13, 3 BCL2-BCL2 mbrf)/D 2). As shown in Table
VII, V(D)J-mediated breaks occurred at high frequency at
the 3 BCL2 RSS (100%), but not in the BCL2 mbrf. These
data first validates the suggestion of Vaandrager et al. that
the transposition process they observed was indeed medi-
ated by V(D)J recombination (33). Most importantly, these
results show that the relative recombination rate of  5% in
vivo, corresponds to a relative V(D)J-recombination rate of
100% in our ex vivo assay, and therefore that BCL2 mbr
breaks are not generated by V(D)J mis-targeting. No such
relative frequencies can be directly assessed for BCL1 mtc in
vivo. Nevertheless, considering the similar, very characteris-
tic features of BCL1 mtc and BCL2 mbr translocation
breakpoints, and the equal absence of V(D)J recombination
at the detection limits of our assay, it is very unlikely that
the cryptic sites in BCL1 mtc are involved in the initiation
of t(11;14)(q13;q21).
This strongly supports the view that both t(14;18)(q32;
q21) and t(11;14)(q13;q21) translocations belong to a cate-
gory of translocation distinct from type 1, in which only the
breaks at the immune locus are mediated by V(D)J recom-
bination. Breaks at the nonimmune locus bearing the proto-
oncogene are therefore initiated by other mechanisms, and
could subsequently invade the V(D)J synaptic complex dur-
ing the rearrangement process. Such translocation mecha-
nism will be referred to as “type 2” in this manuscript.
Precise Quantification of the Recombinogenic Potentials of the
Proto-oncogene Breakpoint Regions in Type 1 Translocations.
To determine if the recombination rates of the functional
cryptic RSSs in type 1 translocations are sufficient to com-
pete with physiological TCR RSSs, we performed com-
petition assays in which the proto-oncogene breakpoint
region competes for recombination with the normal part-
ner of the immune locus to which it translocates. In these
competition assays, the presence of the two competing
segments on the same plasmid allows a direct and very pre-
cise estimation of the relative rates of recombination (10).
This is demonstrated here by the (1:1) relative ratio ob-
tained for a control substrate in which the two compet-
ing segments are identical (D 1.1/(TAL2-TAL2), Table
VIII). Thus, to estimate the recombinogenic potential of
the TAL2 sequence, the TAL2 segment was set to com-
pete with J 2.7 for rearrangement to D 1.1 (Fig. 2, line
15, D 1.1/(TAL2-J 2.7)). As shown in Table VIII, the
rate of recombination of TAL2 RSS is  50 times lower
than its J 2.7 physiological competitor (2 vs. 98%). A sim-
ilar type of experiment was performed for LMO2. The J 1
segment was used as competitor for rearrangement to D 2
(Fig. 2, line 16, LMO2i-J 1i)/D 2i). Strikingly, results in
Table VIII indicate that the recombination frequency of
the LMO2 RSS (25%) displayed only a threefold decrease
relatively to the J 1 RSS (75%). This is slightly different
from the estimation of Raghavan et al. (12) who found a
27-fold lower recombinogenic potential relative to a con-
sensus 12-signal. However, their estimation is based on
comparison with a standard consensus RSS, while we used
the natural J 1 competitor of the t(11;14)(p13;q11) trans-
location which diverges from consensus at several posi-
tions (Table I).
Thus, precise quantification of the recombinogenic po-
tentials of the TAL2 and LMO2 proto-oncogene break-
point regions show that they are essentially in the same
range as the physiologic recombination partners of the
TCR D  and D  gene segments. Importantly, if the po-
tency of a fortuitous RSS largely contributes to the final
frequency of translocation in vivo, recombinogenic poten-
tials in this range should constitute a considerable risk of
genomic instability and cancer through mis-targeting by
the V(D)J recombination.
The Recombinogenic Potential of the LMO2 Breakpoint Re-
gion Is Directly Predictive of the t(11;14)(p13;q11) Translocation
Frequency In Vivo. To test the contribution of the re-
combinogenic potential of the LMO2 proto-oncogene
breakpoint region in the final frequency of the t(11;14)
(p13;q11) translocation, we sought to detect the D 2/
LMO2 rearrangement in vivo, and to assess if the relative
frequency of translocation matches the relative frequency
of recombination determined ex vivo. To minimize possi-
ble bias from subsequent selection and proliferation of ma-
lignant cells carrying the specific translocation in vivo, we
used thymus from healthy individuals as the source of
Table VIII. Competition Substrates
Vector
(internal-external)
No.
T
No.
clones
No.
A Internal : External
D 1/(TAL2-TAL2) 4  418 70 33a (49%) : 34 (51%)
D 1/(TAL2-J 2.7) 4  1,600 89 2 (2%) : 87 (98%)
D 2/(J 1-LMO2) 2  279 71 53 (75%) :  18 (25%)
aThe three remaining clones consist of recombination to cryptic sites or
of BR.94 Genomic Instability by Cryptic RSS
DNA. In thymus DNA, however, the frequency of D 2/
LMO2 translocation cannot be assessed relatively to the
D /J  rearrangements for two main reasons: (a) D /J  re-
arrangements are subject to differentiation and selection in
normal thymus; (b) D /J  rearrangements occur in cis, i.e.,
by deletion on the same chromosome, while D 2/LMO2
rearrangements occur in trans, i.e., by translocation be-
tween two chromosomes. Trans-chromosomal V(D)J re-
combination has been estimated to be at least 1,000 times
less abundant than standard V(D)J recombination within a
given receptor locus (34, 35). We reasoned therefore that
since the LMO2 recombinogenic potential is comparable
to those of authentic TCR RSSs, its rate of translocation
with TCR gene segments should be comparable to the
rates of TCR trans-chromosomal V(D)J recombination
(e.g., TCR / ). We thus compared the relative in vivo
frequencies of t(11;14)(p13;q11) (D 2/LMO2) and t(7;14)
(q34;q11) (D 2/J 2.7) V(D)J-mediated translocations.
To detect D 2/LMO2 and D 2/J 2.7 rearrangements,
which were anticipated to be rare in thymus DNA of
healthy individuals, we used a sensitive double nested PCR
assay, in a “multiple tube” procedure (29). Detection of
rare events by such sensitive PCR assay gives rise to fluctu-
ation, probably depending on the presence or not of the
event in the aliquot taken from the sample, and on how
early in the PCR cycling the event is first amplified. To
circumvent this fluctuation, each individual estimate is
based on the sum of PCR products from 20–40 separate
reactions, analyzed in parallel lanes. The results obtained
from 3 independent thymuses are summarized in Table IX,
and representative PCR signals are shown in Fig. 4. As can
be seen, D 2/LMO2 signal joints could be detected at a
strikingly high rate (55/100 [55%] reactions in 2/3 thy-
muses), which can be roughly estimated at  1 transloca-
tion event every 1–10   105 cells (34). To confirm the
identity of the D 2/LMO2 rearrangements, the PCR
bands were cloned and sequenced. All bands sequenced
showed the presence of a proper D 2/LMO2 signal joint
(see online supplemental sequences). Importantly, these
breakpoints are also qualitatively similar to the two D 2/
LMO2 derivative chromosome 11 breakpoints described so
far at that site in T-ALL (19), and to the junctions gener-
ated ex vivo in this study. In addition, comparison between
D 2/LMO2 and D 2/J 2.7 recombination rates shows
that the appearance of D 2/LMO2 rearrangements strik-
ingly parallels the one of D 2/J 2.7 rearrangements (Table
IX, 25/60 [42%] reactions in 2/3 thymuses). The absence
of detection of both translocations in thymus 2 is not due
to differences in DNA quality (see Materials and Methods)
and could be related to age difference. To exclude possible
bias due to differences in the efficiency of the PCR primer
combinations used, each PCR amplification was calibrated.
Serial dilutions of a plasmid containing either a D 2/
LMO2, or a D 2/J 2.7 rearrangement were PCR-ampli-
fied using the same sets of nested primers as above. Both
rearrangements could be detected with a comparable sensi-
tivity (not shown), indicating that there is no large bias in
the PCR detection of the rearrangements. This suggests
that the t(11;14)(p13;q11) involving D 2/LMO2 recombi-
nation, and the t(7;14)(q34;q11) involving TCR D 2/J 
recombination, occur at similar frequencies in the thymus
of healthy individuals.
Remarkably, these data show that: (a) the t(11;14)
(p13;q11) involving D 2/LMO2 recombination previously
found only in T-ALL patients, can also be detected at high
frequency in thymus from healthy individuals; and (b) the
recombinogenic potential of LMO2, as assessed in recom-
bination assays ex vivo, is directly predictive of the actual in
vivo rate of translocation.
Discussion
Lymphoid neoplasms (NHL and ALL) are among the
most frequent malignancies. In industrial countries, their
incidence is increasing more rapidly than that of most other
tumors, but the reasons for this progression are largely un-
explained. Multiple factors are likely to be involved, and
act over the lifetime of an individual through many patho-
genic pathways, rendering causal relationships complex. It
is therefore of considerable importance to gain further un-
derstanding on the initial molecular mechanisms involved
in lymphomagenesis, and on the role played by genetic and
exogenous factors in this process. The recombination assay
described here provides a functional mean by which such
studies can be initiated.
Our data indicate that at least two distinct mechanisms
involving V(D)J recombination can lead to translocation, as
previously anticipated on the basis of in vivo translocation
Table IX. In Vivo Frequencies of Translocation
Thymus (age) D 2/LMO2 D 2/J 2.7
1 (6 yr) 16/40 12/20
2 (2 d) 0/20 0/20
3 (1 yr) 39/40 13/20
Total 55/100 ( 55%) 25/60 ( 42%)
Figure 4. Detection of t(11;14)(p13;q11) (D 2/LMO2) and t(7;14)
(q34;q11) (D 2/J 2.7) V(D)J-mediated translocations by the multiple
tube procedure. Reactions 1–5 from thymus 1 and 3 are shown.95 Marculescu et al.
breakpoints analysis (Fig. 5): in a first category (type 1), ille-
gitimate V(D)J recombination would occur between a le-
gitimate Ig or TCR locus and an illegitimate proto-onco-
gene locus bearing a fortuitous but functional RSS (Fig. 5,
middle panel). Together with the breakpoint features pre-
viously observed in vivo in T-ALL, our results strongly
support the possibility that most t(7;9)(q34;q32), t(11;14)
(p13;q11), and t(1;14)(p34;q11) are mediated by such
type 1 mechanism. In a second category of translocation
(type 2), only the Ig/TCR loci breaks are mediated by
V(D)J recombination (Fig. 5, right panel). Breaks at the
nonimmune locus bearing the proto-oncogene, are there-
fore initiated by other mechanisms, and could subsequently
invade the V(D)J synaptic complex during the rearrange-
ment process (also called “strand donation,” [35;36]). Our
data indicate that the t(11;14)(q13;q32), and t(14;18)
(q32;q21) translocations in NHL are very likely to belong
to this second category, in full agreement with the predic-
tions based on the most recent in vivo observations (28, 37).
Interestingly, the three translocations identified above as
type 1 correspond to the translocations associated with the
development of T cell malignancies, while the two translo-
cations identified as type 2 are the ones associated with the
development of B cell neoplasms. This could reflect a more
general difference between B and T cells toward regulation
of locus accessibility. Indeed, several lines of evidence sug-
gest that the accessibility to the V(D)J recombinase is more
tightly restricted to the Ig loci in B cells than it is to the
TCR loci in T cells (38–40). In this scenario, the accessi-
bility of the recombinase to nonimmune loci such as proto-
oncogenes would be inhibited in B cells, and other mecha-
nisms would then be necessary to generate the breaks near
the various proto-oncogene loci.
For type 1 translocations, mis-targeting by the V(D)J re-
combination in developing T cells should present a con-
siderable risk of genomic instability and cancer: (a) even
sublevels of V(D)J mis-targeting can lead to chromosomal
alterations, as previously observed for chromosomal dele-
tion (2), and as shown in this report for chromosomal
translocation with TAL1/D ; (b) an estimated 10 million
fortuitous cryptic sites in the genome could potentially
mis-target the V(D)J recombination process at  1% the
range of canonical frequency (2), a frequency well above
that of TAL1; and (c) the genomic instability conferred by
V(D)J mis-targeting can be considerable, as demonstrated
here by the high recombinogenic potential of the LMO2
sequence tested and correspondingly high rates of D 2/
LMO2 translocation in healthy individuals. This major
Figure 5. Legitimate and illegitimate V(D)J recom-
bination. Two models of V(D)J-mediated translocation
are shown: type 1 translocation (middle panel) results
from V(D)J recombination between a fortuitous but
functional RSS in the proto-oncogene sequence; in
type 2 translocations (right panel) DSBs at the proto-
oncogene locus are created by a yet unknown mecha-
nism and the resulting DNA broken ends subsequently
invade the V(D)J synapse at the Ig/TCR locus. The D
gene segments (D’s) are represented as black boxes
with their corresponding RSSs as white triangles. The J
gene segments (J’s) are shown as white boxes with their
RSSs as black triangles. (A) Genomic configuration. Pu-
tative chromosomes are indicated. Arrows indicate the
sites of V(D)J-mediated cleavage during the attempted
rearrangement. The broken arrow with question mark
shows the site of breakage by a mechanism distinct from
V(D)J-mediated cleavage. (B) The cleaved signal com-
plex stage of the rearrangement and end-joining. (C)
Rearranged configuration.96 Genomic Instability by Cryptic RSS
impact of the recombinogenic potential of a RSS is sur-
prising in the view that several additional factors are ex-
pected to play an important role in the outcome of the
translocation: the accessibility of the recombinase to a
given locus; the inhibition of trans-chromosomal V(D)J
recombination; the recently described post-cleavage spe-
cificity of the V(D)J machinery (41); and the selection
and proliferation of cells carrying the translocation due to
the ectopic expression of the proto-oncogene. Some of
these factors, such as the one responsible for the inhibi-
tion of trans-locus recombination, are likely to be general
mechanisms which should be operating equally in all
translocations, regardless of the involvement of an im-
mune or nonimmune locus. However, some others, such
as accessibility, should be more locus dependent (42). We
cannot exclude the possibility that the LMO2 locus is ac-
cidentally relatively accessible to the recombinase in de-
veloping T cells, but that this situation might be different
for other proto-oncogene loci. Interestingly, trans-V(D)J
recombination between immune loci has been previously
described as a potent bio-marker for genomic instability
and cancer (43). It will be of importance to determine in
prospective studies if the rate of type 1 translocations and
the development of the corresponding associated neo-
plasms, is also upmodulated in the situations of genomic
instability identified by trans-locus V(D)J recombination.
The understanding of the regulating forces involved in
type 1 translocation, and the identification of the possible
genetic or exogenous factors involved in their modula-
tion, might prove to be important steps in cancer pre-
vention.
For type 2 translocations, the identification of the addi-
tional mechanisms involved in the translocation processes is
the present challenge in the further understanding of this
type of illegitimate recombination. Numerous mechanisms
have previously been proposed as potential candidates, in-
cluding CHI sequences (44, 45), 2-ended transposition (46,
47), and the somatic hypermutation mechanism (28). Inter-
estingly, the possible involvement of the somatic hypermu-
tation as the additional mechanism generating the breaks at
the proto-oncogene locus, would be in line with the asso-
ciation between type 2 translocations and mature B cell
malignancies. On the other hand, the lack of obvious con-
sensus motifs found so far between the BCL1 mtc and the
BCL2 mbr despite the striking similarities in the t(14;18)
(q32;q21) and t(11;14)(q13;q32) junctions, might suggest a
difference in the origin of the specific breakage, but a com-
mon mechanism of invasion of the V(D)J synapse by the
broken ends. One could conceive that various causes of
breakage could all eventually lead to broken ends trapped
in the same DNA/protein repair complex (e.g. through re-
cruitment of Ku70/80). In support of this scenario, it
would be of interest to determine if “naked” broken ends
can invade the specific V(D)J synaptic complex, in absence
of mechanisms other than the ubiquitous DNA repair pro-
cess. If so, the contribution of V(D)J recombination to ge-
nomic instability could be the result of more diverse and
complex processes than previously anticipated.
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